Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
39 pending office actions • 4 clients • 35 examiners • 23 art units • 0 of 39 (0%) have an AI response strategy ready • 35 patents granted in the last 365 days
Taft Law reports 7569 career applications in Biotechnology & Pharmaceuticals and 39 pending office actions. The application figure indicates a broad prosecution history, while the pending docket reflects ongoing office-action activity in the reported field.
The resolved allowance rate is 85.85%, and the average is 2.85 office actions per allowance. Resolved matters have commonly reached allowance, with allowances generally associated with several prosecution events. These metrics give practitioners separate information about disposition outcomes and the interaction required to reach allowance.
The portfolio-level record is useful for evaluating reported experience and current workload together. It does not disclose claim scope, examiner variation, or the circumstances of individual applications, so it should guide additional review rather than determine expectations for a new matter.
Based on the USPTO statutory response window for each pending office action. 18 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 18 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 2 (5%) |
| §101 + other | 15 (38%) |
| §103 only | 6 (15%) |
| §102 only | 1 (3%) |
| §112 only | 3 (8%) |
| Double-patenting + other | 1 (3%) |
| Multi-statute (no §101) | 11 (28%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LANKFORD JR, LEON B | 3 | 70.0% | +31.5% |
| CHIU, MAY LEUNG | 2 | 43.3% | +26.1% |
| NGUYEN, NAM P | 2 | 54.8% | +48.7% |
| BUTLER, SARAI E | 1 | 88.2% | +10.6% |
| WANG, JING | 1 | 100.0% | +0.0% |
| BORTOLI, JONATHAN | 1 | 76.4% | +40.2% |
| HUANG, WEN | 1 | 82.0% | +22.7% |
| JORGENSEN, ABBY A | 1 | 73.7% | +14.4% |
| NGUYEN, BAO THUY L | 1 | 41.8% | +22.0% |
| WHATLEY, BENJAMIN R | 1 | 66.7% | +68.3% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18667208 | OPTICAL SYSTEM FOR FOURIER PTYCHOGRAPHY | HUANG, WEN | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17891458 | IDENTIFICATION OF PATIENTS WITH ABNORMAL FRACTIONAL SHORTENING | MARCSISIN, ELLEN JEAN | 51d overdue |
| 18352183 | PROGNOSTIC VALUE OF BIOMARKERS IN PATIENTS WITH NON-SMALL CELL LUNG CANCER HAVING STABLE DISEASE | SINES, BRIAN J | 30d overdue |
| 18556849 | INFORMATION PROCESSING DEVICE FOR PROVIDING REFERENCE INFORMATION RELATING TO DIAGNOSIS OF THYROID DISEASE | HRANEK, KAREN AMANDA | 25d overdue |
| 18561621 | sFRP4 AS BLOOD BIOMARKER FOR THE NON-INVASIVE DIAGNOSIS OF ADENOMYOSIS | COUNTS, GARY W | 8d overdue |
| 17916251 | A METHOD OF ASSESSING A FEMALE'S RISK OF HAVING PCOS AS WELL AS PRODUCTS AND USES RELATING THERETO | VOLKOV, ALEXANDER ALEXANDROVIC | 4d overdue |
| 17931993 | CARRY-OVER MONITORING | HILL, GRACELYN MARKHAM | 13d |
| 17360121 | DETECTION OF BACTERIAL (MOLLICUTIES) CONTAMINATION | BERTAGNA, ANGELA MARIE | 14d |
| 17447844 | METHOD FOR DETERMINING AT LEAST ONE STATE OF AT LEAST ONE CAVITY OF A TRANSPORT INTERFACE CONFIGURED FOR TRANSPORTING SAMPLE TUBES | SKIBINSKY, ANNA | 16d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18649151 | TRANSPORT DEVICE AND LABORATORY SAMPLE DISTRIBUTION SYSTEM | JORGENSEN, ABBY A | 3d overdue |
| 15892829 | ALKALINE PRETREATMENT OF PARVOVIRUSES FOR IMMUNOASSAYS | NGUYEN, NAM P | 26d |
| 17838568 | PARTICLE-BASED IMMUNOASSAY USING A PEGYLATED ANALYTE-SPECIFIC BINDING AGENT | NGUYEN, NAM P | 34d |
| 17814332 | SAMPLE INPUT INTERFACE | CHIU, MAY LEUNG | 54d |
| 19288563 | METHOD FOR DETECTING AND REPORTING AN OPERATION ERROR IN AN IN-VITRO DIAGNOSTIC SYSTEM AND AN IN-VITRO DIAGNOSTIC SYSTEM | BUTLER, SARAI E | — |
| 18668368 | METHOD AND SYSTEM FOR OPERATING A LABORATORY AUTOMATION SYSTEM | BORTOLI, JONATHAN | — |
| 18667208 | OPTICAL SYSTEM FOR FOURIER PTYCHOGRAPHY | HUANG, WEN | — |
| 18645358 | ON-BOARD CONJUGATION | NGUYEN, BAO THUY L | — |
| Client (Assignee) | Pending OAs |
|---|---|
| ROCHE DIAGNOSTICS OPERATIONS, INC. | 36 |
| Mochida Pharmaceutical | 1 |
| Roche Diagnostics Operations, Lnc. | 1 |
| Roche Diagnostics Operations, Inc. | 1 |
| Art Unit | Apps |
|---|---|
| 1678 | 7 |
| 1797 | 4 |
| 1677 | 3 |
| 1657 | 3 |
| 1798 | 2 |
| 1796 | 2 |
| 1758 | 2 |
| 2114 | 1 |
| 2881 | 1 |
| 2872 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19288563 | METHOD FOR DETECTING AND REPORTING AN OPERATION ERROR IN AN IN-VITRO DIAGNOSTIC SYSTEM AND AN IN-VITRO DIAGNOSTIC SYSTEM | Roche Diagnostics Operations, Inc. | BUTLER, SARAI E | 2114 | §103§112Other | Non-Final OA | — | Pending | Aug 01, 2025 |
| 18719252 | METHOD FOR CHARACTERIZATION OF A MASS SPECTROMETRY INSTRUMENT COMPRISING AT LEAST ONE MASS ANALYZING CELL | Roche Diagnostics Operations, Inc. | WANG, JING | 2881 | §101§103§112 | Non-Final OA | — | Pending | Jun 12, 2024 |
| 18668368 | METHOD AND SYSTEM FOR OPERATING A LABORATORY AUTOMATION SYSTEM | Roche Diagnostics Operations, Inc. | BORTOLI, JONATHAN | 1797 | §101 | Non-Final OA | — | Pending | May 20, 2024 |
| 18667208 | OPTICAL SYSTEM FOR FOURIER PTYCHOGRAPHY | Roche Diagnostics Operations, Inc. | HUANG, WEN | 2872 | §103 | Final Rejection | — | Pending | May 17, 2024 |
| 18649151 | TRANSPORT DEVICE AND LABORATORY SAMPLE DISTRIBUTION SYSTEM | Roche Diagnostics Operations, Inc. | JORGENSEN, ABBY A | 3651 | §103 | Non-Final OA | 3d overdue | Pending | Apr 29, 2024 |
| 18645358 | ON-BOARD CONJUGATION | Roche Diagnostics Operations, Inc. | NGUYEN, BAO THUY L | 1677 | §102§103 | Non-Final OA | — | Pending | Apr 24, 2024 |
| 18642895 | ADJUSTABLE ADAPTER AND LABORATORY SYSTEM | Roche Diagnostics Operations, Inc. | WHATLEY, BENJAMIN R | 1798 | §102§103§112 | Non-Final OA | — | Pending | Apr 23, 2024 |
| 18696730 | MR-PROADM MARKER PANELS FOR EARLY DETECTION OF SEPSIS | Roche Diagnostics Operations, Inc. | LEE, JAE W | 1759 | §101§103§112 | Non-Final OA | — | Pending | Mar 28, 2024 |
| 18692099 | CENTERING HOLDER FOR CENTERING ONE SAMPLE TUBE | Roche Diagnostics Operations, Inc. | WRIGHT, PATRICIA KATHRYN | 1798 | §112 | Non-Final OA | — | Pending | Mar 14, 2024 |
| 18433619 | CHIMERIC IGG-FC-BINDING LIGAND POLYPEPTIDE AND USES THEREOF FOR IGG AFFINITY PURIFICATION | Roche Diagnostics Operations, Inc. | SZPERKA, MICHAEL EDWARD | 1641 | §103§112 | Non-Final OA | — | Pending | Feb 06, 2024 |
| 18542054 | THERMOSTABLE AFFINITY POLYPEPTIDES | Roche Diagnostics Operations, Inc. | HAUK TEODORO, PRICILA NMN | 1645 | §112 | Final Rejection | 57d | Pending | Dec 15, 2023 |
| 18541476 | METHOD FOR IMMUNOSENSING ON A LIPID LAYER | Roche Diagnostics Operations, Inc. | DUNN, MCKENZIE A | 1678 | §102§103DP | Non-Final OA | — | Pending | Dec 15, 2023 |
| 18541343 | METHOD FOR DIGITAL IMMUNOSENSING ON SINGLE MOLECULES USING LABEL IMMOBILIZATION AND AMPLIFICATION STRATEGY | Roche Diagnostics Operations, Inc. | IVICH, FERNANDO NMN | 1678 | §102§103§112 | Non-Final OA | — | Pending | Dec 15, 2023 |
| 18541624 | UNIVERSAL CALIBRATION FOR QUANTITATIVE MASS SPECTROMETRY | Roche Diagnostics Operations, Inc. | ALABI, OYELEYE A | 1797 | §101§102§103§112 | Non-Final OA | — | Pending | Dec 15, 2023 |
| 18561621 | sFRP4 AS BLOOD BIOMARKER FOR THE NON-INVASIVE DIAGNOSIS OF ADENOMYOSIS | Roche Diagnostics Operations, Inc. | COUNTS, GARY W | 1678 | §101 | Non-Final OA | 8d overdue | Pending | Nov 16, 2023 |
| 18558150 | ESM1 MARKER PANELS FOR EARLY DETECTION OF SEPSIS | Roche Diagnostics Operations, Inc. | LANKFORD JR, LEON B | 1657 | §103 | Non-Final OA | — | Pending | Oct 30, 2023 |
| 18558133 | IL6 MARKER PANELS FOR EARLY DETECTION OF SEPSIS | Roche Diagnostics Operations, Inc. | LANKFORD JR, LEON B | 1657 | §103 | Non-Final OA | — | Pending | Oct 30, 2023 |
| 18557890 | PRESEPSIN MARKER PANELS FOR EARLY DETECTION OF SEPSIS | Mochida Pharmaceutical Co., Ltd. | LANKFORD JR, LEON B | 1657 | §102§112 | Non-Final OA | — | Pending | Oct 27, 2023 |
| 18556849 | INFORMATION PROCESSING DEVICE FOR PROVIDING REFERENCE INFORMATION RELATING TO DIAGNOSIS OF THYROID DISEASE | Roche Diagnostics Operations, Inc. | HRANEK, KAREN AMANDA | 3684 | §101§103 | Final Rejection | 25d overdue | Pending | Oct 23, 2023 |
| 18468249 | HIGHLY WATER-SOLUBLE AND STABLE CHEMOSENSOR FOR CYSTEINE | Roche Diagnostics Operations, Inc. | BROOKS, CLINTON A | 1621 | §103§112 | Non-Final OA | — | Pending | Sep 15, 2023 |
| 18352183 | PROGNOSTIC VALUE OF BIOMARKERS IN PATIENTS WITH NON-SMALL CELL LUNG CANCER HAVING STABLE DISEASE | Roche Diagnostics Operations, Inc. | SINES, BRIAN J | 1796 | §101§102§103§112 | Final Rejection | 30d overdue | Pending | Jul 13, 2023 |
| 18339760 | AUTOMATED CLINICAL DIAGNOSTIC SYSTEM AND METHOD | Roche Diagnostics Operations, Inc. | WALLENHORST, MAUREEN | 1797 | §102§103§112 | Non-Final OA | — | Pending | Jun 22, 2023 |
| 18333347 | INTERFERENCE MONITORING FOR PROVIDING A VERIFIED ANALYTE MEASUREMENT | Roche Diagnostics Operations, Inc. | HYUN, PAUL SANG HWA | 1796 | §101§102§103§112 | Final Rejection | 33d | Pending | Jun 12, 2023 |
| 18309985 | TIMP1 AS A MARKER FOR CHOLANGIOCARCINOMA | Roche Diagnostics Operations, Inc. | DENT, ALANA HARRIS | 1643 | §102 | Final Rejection | 20d | Pending | May 01, 2023 |
| 18017073 | GDF-15 FOR PREDICTING THE DISEASE SEVERITY OF A PATIENT WITH COVID-19 | Roche Diagnostics Operations, Inc. | ZOU, NIANXIANG | 1671 | §101§103 | Final Rejection | 61d | Pending | Jan 19, 2023 |
| 17990903 | REAGENT FOR MASS SPECTROMETRY | Roche Diagnostics Operations, Inc. | ADAMS, MICHELLE | 1797 | §102§112 | Non-Final OA | — | Pending | Nov 21, 2022 |
| 17916251 | A METHOD OF ASSESSING A FEMALE'S RISK OF HAVING PCOS AS WELL AS PRODUCTS AND USES RELATING THERETO | Roche Diagnostics Operations, Inc. | VOLKOV, ALEXANDER ALEXANDROVIC | 1677 | §101§103§112 | Final Rejection | 4d overdue | Pending | Sep 30, 2022 |
| 17931993 | CARRY-OVER MONITORING | Roche Diagnostics Operations, Inc. | HILL, GRACELYN MARKHAM | 1685 | §101§103 | Non-Final OA | 13d | Pending | Sep 14, 2022 |
| 17891458 | IDENTIFICATION OF PATIENTS WITH ABNORMAL FRACTIONAL SHORTENING | Roche Diagnostics Operations, Inc. | MARCSISIN, ELLEN JEAN | 1677 | §101§103§112 | Final Rejection | 51d overdue | Pending | Aug 19, 2022 |
| 17814332 | SAMPLE INPUT INTERFACE | Roche Diagnostics Operations, Inc. | CHIU, MAY LEUNG | 1758 | §102§103§112 | Final Rejection | 54d | Pending | Jul 22, 2022 |
| 17838568 | PARTICLE-BASED IMMUNOASSAY USING A PEGYLATED ANALYTE-SPECIFIC BINDING AGENT | Roche Diagnostics Operations, Inc. | NGUYEN, NAM P | 1678 | §103 | Final Rejection | 34d | Pending | Jun 13, 2022 |
| 17805899 | METHOD AND DEVICE FOR MULTIPLE TRANSITION MONITORING | Roche Diagnostics Operations, Lnc. | ANDERSON-FEARS, KEENAN NEIL | 1687 | §101§103§112 | Final Rejection | — | Pending | Jun 08, 2022 |
| 17660299 | PREANALYTIC SYSTEM FOR PREPARING A LABORATORY SAMPLE CONTAINER | Roche Diagnostics Operations, Inc. | CHIU, MAY LEUNG | 1758 | §103 | Final Rejection | — | Pending | Apr 22, 2022 |
| 17575202 | S100A12 AS BLOOD BIOMARKER FOR THE NON-INVASIVE DIAGNOSIS OF ENDOMETRIOSIS | Roche Diagnostics Operations, Inc. | MONTGOMERY, ANN Y | 1678 | §101§103§112 | Final Rejection | 28d | Pending | Jan 13, 2022 |
| 17447844 | METHOD FOR DETERMINING AT LEAST ONE STATE OF AT LEAST ONE CAVITY OF A TRANSPORT INTERFACE CONFIGURED FOR TRANSPORTING SAMPLE TUBES | Roche Diagnostics Operations, Inc. | SKIBINSKY, ANNA | 1635 | §101§103 | Non-Final OA | 16d | Pending | Sep 16, 2021 |
| 17360121 | DETECTION OF BACTERIAL (MOLLICUTIES) CONTAMINATION | Roche Diagnostics Operations, Inc. | BERTAGNA, ANGELA MARIE | 1681 | §101§103 | Final Rejection | 14d | Pending | Jun 28, 2021 |
| 17150504 | METHODS OF IDENTIFYING AN INDIVIDUAL AS HAVING OR BEING AT RISK OF DEVELOPING AN AMYLOID-POSITIVE DEMENTIA BASED ON MARKER MOLECULES AND RELATED USES | Roche Diagnostics Operations, Inc. | RAMADAN, OMAR | 1678 | §101§102§103§112 | Final Rejection | — | Pending | Jan 15, 2021 |
| 16008281 | FKBP DOMAIN WITH TRANSGLUTAMINASE RECOGNITION SITE | Roche Diagnostics Operations, Inc. | DABKOWSKI, ERINNE R | 1654 | §112 | Final Rejection | 42d overdue | Pending | Jun 14, 2018 |
| 15892829 | ALKALINE PRETREATMENT OF PARVOVIRUSES FOR IMMUNOASSAYS | Roche Diagnostics Operations, Inc. | NGUYEN, NAM P | 1678 | §103§112 | Non-Final OA | 26d | Pending | Feb 09, 2018 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial85.8% of resolved applications prosecuted by Taft Law were allowed, across 7,569 applications in USPTO records.
2.85 office actions per allowed application on average.
39 pending office actions as of October 2026, for 4 clients, before 35 examiners in 23 art units.
